丙肝肝移植后复发预防策略——Paul Kwo教授现场采访录
——  作者:PaulKwo    时间:2008-05-09     阅读数: 1593

简介:Hepatology Digest:how do you think the clinical practice of proteinase inhibitors ? Will the side effects affect its clinical use? 《国际肝病》:您怎样看待蛋白酶抑制剂在临床上的应用以及这些药物的副作用? Professor Kwo: the proteinase inhibitors will likely be the first small molecular medicine approved for the treatment of genotype 1 hepatitis C. This will greatly improve the cure rate of hepatitis C. Thus far all of the proteinase inhibitors studied to date do have more side effects than peglated interferon and Ribovirin together which also have side effects.

请登录后查看详细内容

发表评论

全部评论
谭怡申2011-01-07 19:51
此栏目办得非常好,谢谢!
rgsxh2010-09-24 17:56
无论是“大三阳”还是“小三阳”的患者,采用核苷(酸)类似物抗病毒治疗,即便是达到指南推荐的停药标准,停药之后仍然有大多数患者复发,只有少数患者持续稳定,因此我国乙型肝炎治疗指南亟待修改!